Clinical Trial Update: Study of Endostar Subcutaneous Injection in NSCLC [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating subcutaneous Endostar for non-small cell lung cancer is listed, with status not yet disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Endostar (recombinant human endostatin)

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: NSCLC | Phase 1 | Status: UNKNOWN